Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glenmark Pharmaceuticals's subsidiary receives final ANDA approval for Telmisartan Tablets


Tuesday, 8 Jul 2014 02:31am EDT 

Glenmark Pharmaceuticals Ltd:Glenmark Generics Inc., USA subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets.Glenmark will commence distribution of product immediately.Telmisartan Tablets are Glenmark’s generic version of Boehringer Ingelheim’s Micardis.Telmisartan is indicated for treatment of hypertension.Approval is for 20mg, 40mg and 80mg tablets.For 12 month period ending March 2014, Telmisartan garnered annual sales of $250 mln according to IMS Health. 

Company Quote

720.55
6.3 +0.88%
22 Aug 2014